sorafenib has been researched along with beta-solamarine in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (beta-solamarine) | Trials (beta-solamarine) | Recent Studies (post-2010) (beta-solamarine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 63 | 2 | 38 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Han, L; Li, X; Long, S; Sheng, H; Tang, Q; Wang, S; Wu, W; Yu, Y | 1 |
1 other study(ies) available for sorafenib and beta-solamarine
| Article | Year |
|---|---|
Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Mucin-1; RNA, Long Noncoding; Solanaceous Alkaloids; Sorafenib | 2022 |